Menopausal Status Linked to Faster Lung Function Decline

This article originally appeared here.
Share this content:
Menopausal Status Linked to Faster Lung Function Decline
Menopausal Status Linked to Faster Lung Function Decline

TUESDAY, Dec. 6, 2016 (HealthDay News) -- Menopausal status is associated with accelerated lung function decline, according to a study published online Dec. 1 in the American Journal of Respiratory and Critical Care Medicine.

Kai Triebner, from the University of Bergen in Norway, and colleagues examined whether lung function decline is accelerated in women undergoing menopause. Serum samples, spirometry, and questionnaire data about respiratory and reproductive health were obtained from three study waves of the population-based longitudinal European Community Respiratory Health Survey (1,438 individuals). The researchers examined the correlation between menopausal status and lung function decline, adjusting for variables including age, height, weight, pack-years, current smoking, and age at completed full-time education.

The researchers found that there was a correlation between menopausal status and accelerated lung function decline. Compared with women menstruating regularly, transitional women and postmenopausal women had increases in the adjusted mean forced vital capacity decline of −10.2 and −12.5 ml/year, respectively. In transitional and postmenopausal women, the adjusted mean forced expiratory volume in one second decline increased by −3.8 and −5.2 ml/year, respectively.

"Lung function declined more rapidly among transitional and postmenopausal women, in particular for forced vital capacity, beyond the expected age change," the authors write. "Clinicians should be aware that respiratory health often deteriorates during reproductive aging."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »